Valuation: AbbVie Inc.

Market Cap 443B 384B 360B 328B 618B 42,301B 628B 4,241B 1,656B 21,175B 1,664B 1,628B 70,638B P/E 2026 *
32x
P/E 2027 * 23.7x
Enterprise Value 504B 436B 409B 373B 702B 48,059B 713B 4,818B 1,881B 24,057B 1,891B 1,850B 80,252B EV / Sales 2026 *
7.45x
EV / Sales 2027 * 6.73x
Free-Float
95.71%
Yield 2026 *
2.73%
Yield 2027 * 2.87%
1 day+0.83%
1 week+2.85%
Current month-0.05%
1 month+1.14%
3 months+20.30%
6 months+8.35%
Current year+9.77%
1 week 244.03
Extreme 244.03
255.3
1 month 241.2
Extreme 241.2
267.47
Current year 190.75
Extreme 190.75
267.47
1 year 190.75
Extreme 190.75
267.47
3 years 135.85
Extreme 135.85
267.47
5 years 105.56
Extreme 105.56
267.47
10 years 55.06
Extreme 55.0623
267.47
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Director

62 0.0000%
30/06/26 Free

Director

134 0.0000%
08/05/26 Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%+2.85%+24.49%+64.82% 443B
-0.92%+1.43%+83.05%+128.86% 1,078B
+0.47%+1.98%+50.26%+50.75% 632B
-0.88%-0.66%+45.09%+36.64% 356B
-0.37%-1.15%+26.89%+36.31% 289B
+0.05%-1.20%+2.31%+6.15% 245B
+0.40%+3.21%+44.42%+59.17% 226B
-0.42%+1.58%-8.48%-51.94% 204B
+1.67%+5.56%+14.98%+72.68% 171B
+1.86%+2.29%+6.52%-25.64% 153B
Average +0.09%+1.48%+28.95%+37.78% 379.64B
Weighted average by Cap. -0.11%+1.33%+44.35%+62.17%

Financials

2026 *2027 *
Net sales 67.58B 58.58B 54.92B 50.07B 94.22B 6,450B 95.73B 647B 252B 3,229B 254B 248B 10,771B 73.51B 63.72B 59.73B 54.46B 102B 7,016B 104B 703B 275B 3,512B 276B 270B 11,716B
Net income 13.86B 12.02B 11.26B 10.27B 19.32B 1,323B 19.63B 133B 51.78B 662B 52.04B 50.91B 2,209B 18.9B 16.38B 15.36B 14B 26.35B 1,804B 26.77B 181B 70.6B 903B 70.96B 69.42B 3,012B
Net Debt 60.33B 52.29B 49.02B 44.7B 84.1B 5,758B 85.45B 577B 225B 2,882B 226B 222B 9,615B 51.47B 44.61B 41.82B 38.13B 71.75B 4,912B 72.9B 492B 192B 2,459B 193B 189B 8,203B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
13/08/26 $250.82 +0.83% 4,370,406
12/08/26 $248.76 -0.53% 3,780,452
11/08/26 $250.09 +0.85% 4,485,470
10/08/26 $247.97 +0.78% 4,209,941
07/08/26 $246.04 +0.89% 4,930,711
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
250.82USD
Average target price
276.24USD
Spread / Average Target
+10.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock